Clinical Trials | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
PhytoSquene now available for clinical and commercial use
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Subscribe To Our Newsletter & Stay Updated
